[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466148":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":140,"collaborators":24,"id":143,"slug":144,"hasResults":145,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":145,"sex":151,"minAge":152,"maxAge":24,"enrollmentInfo":153,"targetDuration":24,"studyType":156,"phases":157,"briefSummary":159,"conditions":160,"keywords":164,"overallStatus":45,"whyStopped":24,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},{"fullName":5,"class":6},"Shanghai Zhongshan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intensive guideline algorithm implementation","EXPERIMENTAL","SGLT2i or GLP-1RA recommended in priority in subjects at very high\u002Fhigh CV risk. The targets of intervention will be achieved at HbA1C \\\u003C7%, blood pressure \\\u003C130\u002F80mmHg， LDL-c\\\u003C1.8mmol\u002FL at very high CV risk or \\\u003C2.6mmol\u002FL at high CV risk patients, antiplatelet as secondary prevention of ASCVD.",[13],"Other: Intensive guideline algorithm implementation",{"label":15,"type":16,"description":17,"interventionNames":18},"Conventional guideline algorithm implementation","ACTIVE_COMPARATOR","Treatment based on the current approaches implemented by local physicians(primary care physicians). Guideline based education and consults will be conducted to primary care physicians.",[19],"Other: Conventional guideline algorithm implementation",[21,25],{"type":6,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"Diabetes guideline pharmacological algorithm will be implemented by primary care physicians in community. In brief, SGLT2i or GLP-1RA will be recommended to control blood glucose in priority when subjects at very high\u002Fhigh CV risk and meet the target HbA1C\\\u003C7%, control blood pressure \\\u003C130\u002F80mmHg， LDL-c\\\u003C1.8mmol\u002FL at very high CV risk patients or \\\u003C2.6mmol\u002FL at high CV risk patients, and antiplatelet as secondary prevention of ASCVD.",[9],null,{"type":6,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"The guideline intervention is based the guidance which the local physicians followed through self learning and education. The management of diabetes paitients will be decided by local physicians.",[15],[29],{"name":30,"affiliation":31,"role":32},"Xiaoying Li, MD","Fudan University","PRINCIPAL_INVESTIGATOR",[34,38],{"name":30,"role":35,"phone":36,"phoneExt":24,"email":37},"CONTACT","13651913857","li.xiaoying@zs-hospital.sh.cn",{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},"Xiaomu Li, MD","13661676591","li.xiaomu@zs-hospital.sh.cn",[43,57,64,69,80,85,91,101,107,113,119,125,135],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":24},"Xiangcheng Second People's Hospital","RECRUITING","Suzhou","Jaingsu","215501","China","CN",{"type":52,"coordinates":53},"Point",[54,55],120.59538,31.30408,{"lat":55,"lon":54},{"facility":58,"status":45,"city":46,"state":59,"zip":60,"country":49,"countryCode":50,"cosmosGeoPoint":61,"geoPoint":63,"contacts":24},"Caohu Community Healthcare Center","Jiangsu","215006",{"type":52,"coordinates":62},[54,55],{"lat":55,"lon":54},{"facility":65,"status":45,"city":46,"state":59,"zip":60,"country":49,"countryCode":50,"cosmosGeoPoint":66,"geoPoint":68,"contacts":24},"Huangqiao Community Healthcare Center",{"type":52,"coordinates":67},[54,55],{"lat":55,"lon":54},{"facility":70,"status":45,"city":46,"state":59,"zip":71,"country":49,"countryCode":50,"cosmosGeoPoint":72,"geoPoint":74,"contacts":75},"Xiangcheng People's Hospital.","215131",{"type":52,"coordinates":73},[54,55],{"lat":55,"lon":54},[76],{"name":77,"role":35,"phone":78,"phoneExt":24,"email":79},"Xuefei Xu, Bachelor","18818211531","pyu15@fudan.edu.cn",{"facility":81,"status":45,"city":46,"state":59,"zip":71,"country":49,"countryCode":50,"cosmosGeoPoint":82,"geoPoint":84,"contacts":24},"Yuanhe Community Healthcare Center",{"type":52,"coordinates":83},[54,55],{"lat":55,"lon":54},{"facility":86,"status":45,"city":46,"state":59,"zip":87,"country":49,"countryCode":50,"cosmosGeoPoint":88,"geoPoint":90,"contacts":24},"Xiangcheng Third People's Hospital","215134",{"type":52,"coordinates":89},[54,55],{"lat":55,"lon":54},{"facility":92,"status":45,"city":46,"state":59,"zip":93,"country":49,"countryCode":50,"cosmosGeoPoint":94,"geoPoint":96,"contacts":97},"Taiping Community Healthcare Center","215137",{"type":52,"coordinates":95},[54,55],{"lat":55,"lon":54},[98],{"name":99,"role":35,"phone":24,"phoneExt":24,"email":100},"Xuejian Ni, Bachelor","2314831056@qq.com",{"facility":102,"status":45,"city":46,"state":59,"zip":103,"country":49,"countryCode":50,"cosmosGeoPoint":104,"geoPoint":106,"contacts":24},"Yangchenghu People's Hospital","215138",{"type":52,"coordinates":105},[54,55],{"lat":55,"lon":54},{"facility":108,"status":45,"city":46,"state":59,"zip":109,"country":49,"countryCode":50,"cosmosGeoPoint":110,"geoPoint":112,"contacts":24},"Health Center of Xiangcheng Tourism Resort","215141",{"type":52,"coordinates":111},[54,55],{"lat":55,"lon":54},{"facility":114,"status":45,"city":46,"state":59,"zip":115,"country":49,"countryCode":50,"cosmosGeoPoint":116,"geoPoint":118,"contacts":24},"Caohu People's Hospital","215144",{"type":52,"coordinates":117},[54,55],{"lat":55,"lon":54},{"facility":120,"status":45,"city":46,"state":59,"zip":121,"country":49,"countryCode":50,"cosmosGeoPoint":122,"geoPoint":124,"contacts":24},"Dongqiao Community Healthcare Center","215152",{"type":52,"coordinates":123},[54,55],{"lat":55,"lon":54},{"facility":126,"status":45,"city":46,"state":59,"zip":127,"country":49,"countryCode":50,"cosmosGeoPoint":128,"geoPoint":130,"contacts":131},"Xiangcheng Traditional Chinese Medicine Hospital","215155",{"type":52,"coordinates":129},[54,55],{"lat":55,"lon":54},[132],{"name":133,"role":35,"phone":24,"phoneExt":24,"email":134},"Jichao Yu, Bachelor","344314300@qq.com",{"facility":136,"status":45,"city":46,"state":59,"zip":24,"country":49,"countryCode":50,"cosmosGeoPoint":137,"geoPoint":139,"contacts":24},"Chengyang Community Healthcare Center",{"type":52,"coordinates":138},[54,55],{"lat":55,"lon":54},{"type":32,"investigatorFullName":141,"investigatorTitle":142,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Xiaoying Li","Chief of Endocrinology Department","100466148","effects-and-safety-of-diabetic-guideline-algorithm-implementation-performed-by-primary-care-physicians-in-the-community-100466148",false,"NCT05349955","Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community","Effects and Safety of GUideline Algorithm Based Intervention on CaRdiovascular and Renal Outcomes in Elderly Diabetic Patients With High Cardiovascular Risk in the Community- A Cluster Randomized Controlled Trial (GUARD-Community Study)","GUARD","Inclusion Criteria:\n\n* ①Males or females aged 65 and above (≥65) receive treatment from the local community health service center;\n* ②Diagnosed type 2 diabetes (ADA criteria):\n* A. Typical symptoms of diabetes + random blood sugar ≥ 11.1mmol\u002FL;\n* B. Fasting blood glucose (FPG) ≥ 7.0mmol\u002FL (fasting blood glucose is defined as no caloric intake within 8 hours);\n* C. Oral glucose tolerance test 2h blood glucose (OGTT) ≥ 11.1mmol\u002FL (2h after meal);\n* D. have been treated with antidiabetic drugs;\n* Each blood sugar test must be repeated to confirm the diagnosis;\n* ③Complicated with chronic kidney disease and\u002For very high\u002Fhigh risk of cardiovascular disease, meet any one of the following:\n* A. ASCVD, including coronary heart disease, cerebral infarction, peripheral vascular disease;\n* B. Or target organ damage (albuminuria, renal impairment with eGFR ≥ 30 ml\u002Fmin\u002F1.73m2, left ventricular hypertrophy or retinopathy);\n* C. ≥ 3 major risk factors (age ≥ 65 years old, hypertension, dyslipidemia, smoking, obesity );\n* D. Diabetes duration ≥ 10 years, with any one traditional cardiovascular risk factor such as advanced age, obesity, smoking, sedentary, family history of cardiovascular disease, hypertension, abnormal lipid metabolism.\n\nExclusion Criteria:\n\n* ①Pregnant women or women planning to become pregnant;\n* ②eGFR\\\u003C30 mL\u002Fmin\u002F1.73m2 (CKD-EPI formula);\n* ③Patient cannot be followed up for 36 months (due to health condition or migration);\n* ④Unwilling or unable to sign the informed consent;\n* ⑤Type 1 diabetes;","ALL","65 Years",{"count":154,"type":155},5600,"ESTIMATED","INTERVENTIONAL",[158],"NA","The Effects and Safety of Diabetic GUideline Algorithm Implementation in the Community (GUARD-Community) study is a 2-arm, cluster-randomized control trial to evaluate the effect and safety of guideline algorithm intervention performed by primary care physicians on cardiovascular and renal outcomes in elderly patients with high risk in community.",[161,162,163],"Type 2 Diabetes","Cardiovascular Complication","Diabetic Kidney Disease",[165,166,167,168],"Diabetes implementation study","Diabetes guideline algorithm","Cardiovascular disease","Chronic kidney disease","2025-05-09",{"date":171,"type":172},"2025-05-14","ACTUAL",{"date":174,"type":172},"2022-11-21",{"date":176,"type":155},"2026-11-30",{"name":5,"class":6},13]